Is FH.NE stock a buy for an oversold bounce?

FH.NE stock may offer a short-term bounce if volume and buyers return. Size positions small, use stops below C$0.005, and aim for partial exits at C$0.015–C$0.02 given high downside risk.

What are the main risks for Filament Health (FH.NE)?

Main risks include negative EPS (-0.02), low current ratio (0.44), thin liquidity, and reliance on biotech licensing or trial news. A lack of positive catalysts can produce further price declines.

What price targets should traders watch for FH.NE stock?

Watch intraday resistance at C$0.015, short-term target C$0.02, and medium-term target C$0.05 per Meyka AI's scenario analysis. Targets require higher volume to be credible.

How does sector context affect FH.NE on NEO?

FH.NE sits in Healthcare where one-year performance is negative; sector pressure lowers odds of a sustained rally. Positive clinical or licensing news would be needed to shift sentiment meaningfully.

CA Stocks

FH.NE Filament Health (NEO) at C$0.01 on 03 Feb 2026: Oversold bounce possible

ByDanny Kontos February 3, 2026February 3, 2026

FH.NE stock is trading at C$0.01 on 03 Feb 2026 during market hours after a one-day drop of 33.33% and volume of 929,483 shares. The NEO-listed Filament Health Corp. (FH.NE) is deep below its 50-day average of C$0.02 and 200-day average of C$0.03, creating a textbook oversold-bounce setup for short-term traders. With EPS at -0.02 and market cap C$3,926,910, we frame a cautious, data-driven bounce plan tied to liquidity, technical resistance, and near-term catalysts.